DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Convergent Therapeutics Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
01/06/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Eventos
Industria
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fuente
Convergent Therapeutics Inc.
Editor
Business Wire
1.00
0
21/05/2026
Ferias y Congresos
Eventos
Industria
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
Fuente
Convergent Therapeutics Inc.
Editor
Business Wire
1.00
0
29/04/2026
Mercado laboral
Ciencia
Medicina - Varios
Biotecnología
Medicina nuclear
Salud
Farmacéutica
Sanidad
Oncología
Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer
Fuente
Convergent Therapeutics Inc.
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Finanzas
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting
Fuente
Convergent Therapeutics Inc.
Editor
Business Wire
1.00
0
19/03/2026
Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors
Fuente
Convergent Therapeutics Inc.
Editor
Business Wire
1.00
0
06/01/2026
Mercado laboral
Industria
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent's Late-Stage Alpha-Emitting Radioantibody Program
Fuente
Convergent Therapeutics Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0